Abstract Library

#4506 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. streptozocin-based chemotherapies (STZ-BC) as first-line (1L) treatment for advanced grade 2/3 (G2/G3) pancreatic NETs (pNETs)

Introduction: The NETTER-2 trial showed improved progression-free survival (PFS) with 1L 177Lu-DOTATATE vs. high dose octreotide in advanced G2/G3 pNETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments, such as STZ-BC, hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Navalkissoor S

Authors: Navalkissoor S, Capdevila J, Deshayes E, Gerard L, Srirajaskanthan R,

Keywords: pancreatic neuroendocrine tumour, [177lu]lu-dotatate, streptozocin, 5-fluorouracil, matching adjusted indirect comparison,

#4293 Efficacy of FOLFOX chemotherapy combined with anti-angiogenic targeted drugs (bevacizumab/surufatinib) in neuroendocrine tumours after progression following multiple lines of therapy: A retrospective study

Introduction: The FOLFOX regimen (combining 5-fluorouracil, leucovorin, and oxaliplatin) has been widely used for treating various cancers, including NETs. However, the effectiveness of combining FOLFOX with antiangiogenic agents in NETs after progression on multiple therapies remains unclear.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Jia X, Sun Z, Chen J,

Keywords: FOLFOX, chemotherapy, antiangiogenic agents, G3,

#4022 Immediate and sustained response of hypoglycaemia to Streptozotocin-based chemotherapy in metastatic Insulinoma: A case report

Introduction: Hypoglycaemia due to insulin production from insulinomas can be challenging to manage. The evidence base for systemic treatment selection is small.

Conference:

Presenting Author:

Authors: Sherriff D, Flanagan D,

Keywords: insulinoma, hypoglycaemia, streptozotocin,

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,

#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan

Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,

Keywords: Streptozocin, pNETs,